Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M. Tanaka H, et al. Among authors: gyotoku h. Eur J Cancer. 2024 Dec;213:115117. doi: 10.1016/j.ejca.2024.115117. Epub 2024 Nov 5. Eur J Cancer. 2024. PMID: 39522333 Free article.
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R. Ogusu S, et al. Among authors: gyotoku h. Cancer Immunol Immunother. 2023 Nov;72(11):3765-3772. doi: 10.1007/s00262-023-03528-x. Epub 2023 Aug 28. Cancer Immunol Immunother. 2023. PMID: 37638979 Free PMC article.
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Takemoto S, Akagi K, Ono S, Tomono H, Honda N, Suyama T, Umeyama Y, Dotsu Y, Taniguchi H, Ogawara D, Senju H, Gyotoku H, Sugasaki N, Yamaguchi H, Nakatomi K, Fukuda M, Mukae H. Takemoto S, et al. Among authors: gyotoku h. Thorac Cancer. 2021 Sep;12(17):2300-2306. doi: 10.1111/1759-7714.14055. Epub 2021 Jul 13. Thorac Cancer. 2021. PMID: 34255933 Free PMC article.
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer.
Taniguchi H, Yamaguchi H, Dotsu Y, Shimada M, Gyotoku H, Senju H, Takemoto S, Kitazaki T, Fukuda M, Ogawara D, Soda H, Nakatomi K, Sugasaki N, Kinoshita A, Nagashima S, Ikeda T, Nakamura Y, Sakamoto N, Obase Y, Fukuda M, Mukae H. Taniguchi H, et al. Among authors: gyotoku h. Thorac Cancer. 2019 Sep;10(9):1764-1769. doi: 10.1111/1759-7714.13134. Epub 2019 Jul 16. Thorac Cancer. 2019. PMID: 31309738 Free PMC article. Clinical Trial.
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Takemoto S, Fukuda M, Yamaguchi H, Ikeda T, Akagi K, Tomono H, Umeyama Y, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Kitazaki T, Nakatomi K, Nagashima S, Fukuda M, Kinoshita A, Soda H, Mukae H. Takemoto S, et al. Among authors: gyotoku h. Thorac Cancer. 2020 Feb;11(2):389-393. doi: 10.1111/1759-7714.13279. Epub 2019 Dec 18. Thorac Cancer. 2020. PMID: 31851428 Free PMC article.
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H. Takemoto S, et al. Among authors: gyotoku h. Thorac Cancer. 2017 Nov;8(6):577-581. doi: 10.1111/1759-7714.12483. Epub 2017 Aug 3. Thorac Cancer. 2017. PMID: 28771961 Free PMC article. Clinical Trial.
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, Ono S, Umeyama Y, Shimada M, Gyotoku H, Takemoto S, Hisamatsu Y, Morinaga R, Tagawa R, Ogata R, Dotsu Y, Senju H, Soda H, Nakatomi K, Hayashi F, Sugasaki N, Kinoshita A, Mukae H. Tomono H, et al. Among authors: gyotoku h. Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675546 Free PMC article.
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.
Akagi K, Taniguchi H, Fukuda M, Yamazaki T, Ono S, Tomono H, Suyama T, Shimada M, Gyotoku H, Takemoto S, Yamaguchi H, Dotsu Y, Senju H, Soda H, Mizowaki T, Monzen Y, Ikeda T, Nagashima S, Tasaki Y, Nakamura D, Komiya K, Nakatomi K, Sasaki E, Hirakawa K, Mukae H. Akagi K, et al. Among authors: gyotoku h. Thorac Cancer. 2022 Aug;13(16):2404-2409. doi: 10.1111/1759-7714.14555. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808894 Free PMC article.
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study).
Takemoto S, Fukuda M, Ogata R, Senju H, Sugasaki N, Nakatomi K, Tomono H, Suyama T, Sasaki E, Matsuo M, Akagi K, Hayashi F, Dotsu Y, Ono S, Honda N, Taniguchi H, Gyotoku H, Ikeda T, Nagashima S, Soda H, Kinoshita A, Mukae H. Takemoto S, et al. Among authors: gyotoku h. Transl Lung Cancer Res. 2024 Oct 31;13(10):2673-2682. doi: 10.21037/tlcr-24-508. Epub 2024 Oct 24. Transl Lung Cancer Res. 2024. PMID: 39507035 Free PMC article.
29 results